2022
Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement
Sahai SK, Balonov K, Bentov N, Bierle DMM, Browning LM, Cummings KC, Dougan BM, Maxwell M, Merli GJ, Oprea AD, Sweitzer B, Mauck KF, Urman RD. Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Mayo Clinic Proceedings 2022, 97: 1734-1751. PMID: 36058586, DOI: 10.1016/j.mayocp.2022.03.039.Peer-Reviewed Original ResearchConceptsCardiovascular medicationsPerioperative assessmentAntiarrhythmic agentsReceptor antagonistAngiotensin receptor neprilysin inhibitorQuality Improvement (SPAQI) Consensus StatementAngiotensin II receptor blockersClass I antiarrhythmic agentsClass III antiarrhythmic agentII receptor blockersClasses of medicationsEndothelin receptor antagonistsPotassium-sparing diureticsCalcium channel blockersΒ-adrenoceptor blockersAdrenergic receptor antagonistPhosphodiesterase-5 inhibitorsEvidence-based recommendationsSodium channel blockersPotassium channel openersSympatholytic medicationsReceptor blockersPerioperative managementHeart failureLoop diuretics
2019
Contemporary personalized β-blocker management in the perioperative setting
Oprea AD, Wang X, Sickeler R, Kertai MD. Contemporary personalized β-blocker management in the perioperative setting. Journal Of Anesthesia 2019, 34: 115-133. PMID: 31637510, DOI: 10.1007/s00540-019-02691-9.Peer-Reviewed Original ResearchConceptsPerioperative β-blocker useΒ-blocker useMajor postoperative cardiac eventsPost-acute myocardial infarctionCardiac adverse eventsPostoperative cardiac eventsSystolic heart failureBeta-adrenergic blockersLong-term treatmentCase-based reviewAdverse eventsCardiac eventsPerioperative periodPerioperative useCardiac surgeryHeart failureMyocardial infarctionPerioperative settingEarlier small-scale studiesTrialsEvaluation trialsPotential benefitsNoncardiacEarlier findingsInfarction